# Practical Druggability Assessment: Research Question Extraction Enhancement
## Executive Summary
**Bottom Line:** All hypotheses face significant commercial and technical barriers. Only **COMT inhibition** and **cholinergic enhancement** offer viable near-term investigation paths, but both have major limitations that make them unlikely commercial prospects.
---
## 1. COMT Inhibition (Dopaminergic Enhancement)
**Revised Confidence: 0.35**
### **Druggability Assessment: MODERATE**
**Existing Compounds:**
- **Tolcapone (Tasmar®)** - Marketed by Valeant/Bausch Health
- **Entacapone (Comtan®)** - Marketed by Orion/Novartis
- **Opicapone (Ongentys®)** - Marketed by BIAL
**Clinical Reality:**
- Tolcapone withdrawn from EU (1998) due to fatal hepatotoxicity (3 deaths/60,000 patients)
- Only available in US with intensive liver monitoring
- Black box warning requires bi-weekly liver function tests
- Entacapone has better safety but weaker CNS penetration
**Competitive Landscape:**
- **No active cognitive enhancement programs** identified
- Academic research only (University of Cambridge, NIMH studies)
- Big pharma abandoned due to safety concerns
**Safety Concerns:**
- **Fatal hepatotoxicity** (1:20,000 risk with tolcapone)
- **Genotype dependency:** Opposite effects in Val158Met carriers
- **Cardiovascular effects:** Orthostatic hypotension, arrhythmias
- **Psychiatric effects:** Hallucinations, dopamine dysregulation syndrome
**Cost & Timeline Estimate:**
- **Phase I safety: $2-3M, 12-18 months**
- **Phase II proof-of-concept: $8-15M, 18-24 months**
- **Total development: $50-80M, 5-7 years** (if safety hurdles cleared)
- **Probability of success: <20%** due to safety profile
**Verdict: HIGH RISK/LOW REWARD** - Fatal hepatotoxicity makes this commercially unviable for healthy populations.
---
## 2. α7 Nicotinic Receptor Agonism (Cholinergic Enhancement)
**Revised Confidence: 0.45**
### **Druggability Assessment: MODERATE-HIGH**
**Existing Compounds & Clinical Graveyard:**
- **EVP-6124 (Encenicline)** - Forum Pharmaceuticals **FAILED Phase 3**
- 2 Phase 3 Alzheimer's trials (NCT01969123, NCT01969136): **TERMINATED 2017**
- 2 Phase 3 Schizophrenia trials: **NO EFFICACY**
- $200M+ investment lost
- **RG3487** - Roche **DISCONTINUED**
- **TC-5619** - Targacept **FAILED Phase 2**
- **AZD0328** - AstraZeneca **DISCONTINUED**
**Why They Failed:**
- **Modest effect sizes** (<0.3 Cohen's d)
- **Rapid receptor desensitization**
- **Narrow therapeutic window**
- **Variable individual responses**
**Competitive Landscape:**
- **Karuna Therapeutics** (acquired by Bristol Myers Squibb for $14B) - different mechanism
- **Cerevel Therapeutics** - moved away from α7
- **Industry consensus:** α7 agonists commercially non-viable
**Safety Profile:**
- Generally well-tolerated
- Mild GI effects, dizziness
- No major safety signals in clinical trials
**Cost & Timeline Estimate:**
- **New α7 program: $100-150M, 6-8 years**
- **Probability of success: <15%** based on track record
- **Better bet:** Novel allosteric modulators, but still unproven
**Verdict: CROWDED GRAVEYARD** - Multiple Big Pharma failures suggest fundamental mechanism limitations.
---
## 3. GABAergic Modulation
**Revised Confidence: 0.25**
### **Druggability Assessment: LOW**
**Existing Landscape:**
- **Benzodiazepines** - cognitive impairing, opposite of desired effect
- **Z-drugs** (zolpidem, etc.) - sedating
- **Positive allosteric modulators** - no marketed cognitive enhancers
**Fundamental Problem:**
- **All GABAergic drugs impair cognition** in healthy individuals
- **Paradoxical enhancement** only seen in pathological conditions
**Safety Concerns:**
- **Dependence and withdrawal**
- **Cognitive impairment**
- **Respiratory depression** (combination risks)
**Verdict: MECHANISTICALLY FLAWED** - GABAergic enhancement consistently impairs rather than improves cognition.
---
## 4. BDNF Enhancement
**Revised Confidence: 0.45**
### **Druggability Assessment: MODERATE (Non-pharmacological)**
**Current Approaches:**
- **Exercise protocols** (most viable)
- **Ketamine** (approved for depression, off-label cognitive use)
- **Transcranial stimulation** + training
**Commercial Reality:**
- **No direct BDNF drugs in development**
- **Exercise programs** not patentable
- **Digital therapeutics** potential market
**Existing Players:**
- **Neurotrack** - digital cognitive training
- **Posit Science** - brain training software
- **Peak** - cognitive enhancement app
**Cost & Timeline:**
- **Digital therapeutic development: $5-15M, 2-3 years**
- **Clinical validation: $10-20M, 3-4 years**
- **Market entry barriers:** Low, but crowded field
**Verdict: VIABLE BUT CROWDED** - Digital health approach most realistic, but limited differentiation.
---
## 5. NMDA Modulation (GRIN2B)
**Revised Confidence: 0.30**
### **Druggability Assessment: POOR**
**Fundamental Issues:**
- **Extremely narrow therapeutic window**
- **Neurotoxicity concerns**
- **No selective GRIN2B modulators available**
**Existing Landscape:**
- **Memantine** (Alzheimer's) - blocks excessive activation
- **Ketamine/esketamine** - NMDA antagonists for depression
- **No cognitive enhancers targeting NMDA**
**Safety Red Flags:**
- **Excitotoxicity risk**
- **Psychotomimetic effects**
- **Cardiovascular effects**
**Verdict: TOO DANGEROUS** - Risk/benefit ratio prohibitive for healthy population use.
---
## 6-7. Parvalbumin Interneurons & Myelin Enhancement
**Revised Confidence: 0.15-0.20**
### **Druggability Assessment: NOT FEASIBLE**
**Technical Barriers:**
- **No selective pharmacological tools**
- **Cannot target specific cell types** with current technology
- **Myelin changes require months/years**
**Verdict: SCIENCE FICTION** - Current technology cannot implement these approaches.
---
## **OVERALL COMMERCIAL ASSESSMENT**
### **Most Viable Path Forward:**
1. **BDNF Enhancement via Digital Therapeutics** - Combine cognitive training with exercise protocols
2. **Genotype-Stratified COMT Studies** - Academic collaboration, not commercial development
### **Why Traditional Pharma Won't Touch This:**
- **Healthy population indication** = extremely high safety bar
- **Modest effect sizes** in cognitive enhancement
- **Regulatory uncertainty** for enhancement vs. treatment
- **Limited market** (research academics)
### **Recommended Strategy:**
**Pivot to validated markets:**
- **ADHD cognitive enhancement** (existing medical need)
- **Age-related cognitive decline** (prevention indication)
- **Digital therapeutics** (lower regulatory burden)
**Total realistic budget:** $15-30M over 3-5 years for digital approach
**Traditional drug development:** Not commercially viable for this indication
**Final verdict:** These hypotheses represent interesting neuroscience but lack practical commercial viability for the stated use case.